The National Institute on Aging Late Onset Alzheimer's Disease Family Based Study:

A Critical Component of the International Effort to Understand Alzheimer's Disease.

Authors:

Dolly Reyes-Dumeyer¹, Kelley Faber², Badri Vardarajan¹, Alison Goate³, Alan Renton³, Michael Chao³, Brad Boeve⁴, Carlos Cruchaga⁵, Margaret Pericak-Vance⁶, Jonathan L. Haines⁷, Roger Rosenberg⁸, Debby Tsuang⁹, Robert A. Sweet¹⁰, David A. Bennett¹¹, Robert S. Wilson¹¹, Tatiana Foroud², Richard Mayeux¹

Affiliations:

¹Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H. Sergievsky Center, Columbia University in the City of New York, NY, USA.

²Department of Medical and Molecular Genetics, National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indiana University School of Medicine, Indianapolis, IN, USA.

³³Department of Genetics & Genomic Sciences, Ronald M. Loeb Center for Alzheimer's disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁴Department of Neurology, Mayo Clinic, Rochester, MN, USA.

⁵ Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.

⁶ John P Hussman Institute for Human Genomics, Dr. John T Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL, USA

⁷Department of Population & Quantitative Health Sciences and Cleveland Institute for Computational Biology. Case Western Reserve University, Cleveland, OH, USA.

⁸ Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA.

⁹GRECC VA Puget Sound, Department of Psychiatry and Behavioral Sciences, University of Washington Seattle, WA, USA

¹⁰Departments of Psychiatry and Neurology, University of Pittsburgh, Pittsburgh, PA, USA.

¹¹Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.

Correspondence:

Richard Mayeux, MD
Neurological Institute
710 West 168th Street
New York, NY 10032
(T) 212 305-2391
Email: rpm2@cumc.columbia.edu

The following authors have no relevant conflicts of interest to report: Dolly Reyes, Kelley Faber, Badri Vardarajan, David A. Bennett, Robert A. Sweet, Roger Rosenberg, Margaret A. Pericak-Vance, Jonathan L. Haines, Tatiana Foroud, Richard Mayeux. Dr. Cruchaga has received research support from: Biogen, Eisai, and Alector, and he has consulted or is a member of the advisory board of Vivid genetics, Halia Therapeutics and Takeda and GSK. Dr. Goate has consulted for Eisai, Pfizer, AbbVie, Cognition Therapeutics, Biogen and is on the scientific advisory board at Genentech.

Abstract: 150

Main Text: 3,344

References: 40

Tables: 4, Figures 2

ABSTRACT

INTRODUCTION: The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study (NIA-LOAD FBS) was established to study the genetic etiology of Alzheimer's disease (AD).

METHODS: Recruitment focused on families with two living affected siblings and a third first degree relative similar in age with or without dementia. Uniform assessments were completed, DNA was obtained as was neuropathology, when possible. *APOE* genotypes, genome-wide SNP arrays and sequencing was completed in the majority of families.

RESULTS: A wide range in the age-at-onset in many large families was related to *APOE* genotype, but not in all. Variants typically associated with early-onset AD and frontotemporal dementia were also found.

DISCUSSION: The NIA-LOAD FBS is the largest collection of familial AD worldwide, and data or samples have been included in 126 publications addressing the genetic etiology of AD. Genetic heterogeneity and variability in the age-at-onset provides opportunities to investigate the complexity of familial AD.

1. Introduction

In 2020, 5.8 million Americans were living with Alzheimer's disease (AD). By 2050 this number is projected to grow to 13.9 million people, nearly 3.3% of the US population¹. The etiology of AD remains unclear, but there is substantial evidence that AD is a highly heritable disorder. The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study (NIA-LOAD FBS) is the largest collection of multiplex AD families recruited and longitudinally assessed worldwide. Since its inception in 2003, the central goal of this cohort was to broadly support genetic research by making clinical and genomic data and biological samples broadly and rapidly available to the AD research community to support the development of therapies to treat or prevent this disease. The use of multiplex families to understand genetic susceptibility to AD began with early onset forms. These studies led to the discovery of rare and highly-penetrant mutations in autosomal dominant AD: *APP*², *PSEN1*^{3,4} and *PSEN2*^{5,6}. Nearly 60% of individuals with early onset AD have other affected family members,⁷ and of these, approximately 13% inherit these mutations in an autosomal dominant manner⁸. While variants in these genes have explained only a small proportion of the occurrence of familial, early-onset AD, they formed the basis for the development of novel therapies now being investigated in patients with AD regardless of age at onset of disease⁹.

Genetic research on the more common late onset form of AD was transformed by the work of Pericak-Vance and her colleagues¹⁰ who used a novel linkage strategy in multiply affected families with late-onset AD. They were the first to identify a locus on chromosome 19¹⁰, which subsequently led to the discovery of the association between the *APOE* ϵ 4 allele and the increased risk of developing AD and the association of the *APOE* ϵ 2 allele and reduced risk^{11,12}. The association was later confirmed in almost all ethnic groups, but with a slightly weaker effect among those with African ancestry¹³. Overall, the population attributable risk of the *APOE*- ϵ 4 allele has been estimated at 20%¹⁴. Nonetheless, the accumulating evidence indicates that late-onset AD is multifactorial with high heritability, 70% or higher, implying that other genes or common risk factors may also contribute to its etiology.

Genetic investigations typically require time and effort to ascertain samples for genetic studies. While it was presumed that recruitment of unrelated patients and controls would be a faster and more efficient way to find risk alleles than families, there are many scientific and practical advantages for recruiting families for genetic research. The observed incidence rates for AD has been estimated to be three to five times higher in multiplex families¹⁵. Multiplex families may be enriched in disease causing genetic variants, allowing penetrance to be studied. This familial enrichment is particularly valuable for rare variants ($MAF < 0.01$), where population-level studies have little power. Family members are generally eager to participate in such research and often have shared environments and parents of origin. Moreover, they also provide the opportunity to assess interaction between alleles at the same locus and to detect epistasis due to the high penetrance.

The NIA-LOAD FBS has contributed to nearly every genetic study of AD and with the advent of novel strategies to understand how genetic variation leads to this disease, it will continue to do so. Here we describe the cohort in detail, show the range of age-at-onset across and within families, the effects of *APOE* on the risk of AD across ethnic groups, the genetic heterogeneity and highlight the broad availability of clinical and genetic data and biological samples.

2. Methods

2.1 Participant recruitment. Families assumed to be multiply affected by AD by history or autopsy were recruited from sites across the United States (supplemental figure 1). The criteria for study entry included two living affected siblings, 60 years of age or older, and a third living relative, similar in age, with or without dementia. We also included families with deceased affected siblings, as long as frozen brain tissue was available for affected members. Families in which participants were symptomatic, but did not meet criteria for AD, were still included with the commitment for follow-up. Healthy controls without a family history of AD in a 1st degree relative, who were 55 years of age or older were also recruited. Participants demonstrated the full range of cognitive function including normal cognition and dementia (table 1). All participants considered to have clinical AD were required to meet established research criteria the disease¹⁶.

Families were enrolled and consented at individual study sites and completed the following protocols either by in person or telephone interview and assessments. The study protocol included: a family pedigree, standardized cognitive and psychiatric assessments, as well as a review of AD and cardiovascular risk factors (table 1). Regular follow-up visits were used to update the family history and obtain additional clinical information on new family members that had not previously participated. All study data were stored at the Columbia University, the Coordinating Center.

2.2 Cognitive assessment. Standardized cognitive assessments began in 2006, and 75% of the cohort has been assessed^{17,18}. The 15-minute cognitive battery consisted of seven brief tests that were administered in person or by telephone and assessed: Working memory - Digit Span Forward and Backward and Digit Ordering; Episodic memory - Immediate and Delayed Recall of story “A” from the Wechsler Memory Scale and Semantic memory - asked persons to name members of two semantic categories (Animals, Vegetables) in separate 1-minute trials. From these measures, a factor analysis of the seven tests summary measures of working memory, declarative memory, episodic memory, semantic memory, and global cognition were developed. The interviews using different methods, in-person or by telephone, had little effect on performance and provided operational flexibility and a means of reducing costs and missing data¹⁷.

2.3 Psychiatric Interview. The assessment of psychiatric manifestations was added in 2010 and was designed to be completed in an interview with a knowledgeable informant and could be conducted after the participant’s death. This approach captured psychotic symptoms that occurred in the prior month, identifying the month during which each symptom was most persistent and recording the frequency of symptoms¹⁹. The Neuropsychiatric Inventory (NPI-Q)^{19,20}, a widely used, validated informant-based interview that is used to evaluate neuropsychiatric symptoms in patients with dementia was selected. The NPI-Q has good interrater reliability and concurrent validity compared with more structured interviews^{21,22}.

2.4 Antecedent risk factors. We collected putative risk and protective factors associated with AD, and at follow-up we reviewed the previous risk factor profiles to update any changes. The primary focus was on modifying factors such as hypertension, heart diseases (myocardial infarction, congestive heart failure, or other type of

heart disease) and diabetes²³. A stroke assessment captured the number of stroke events. The structured interview concerning modifying antecedent (risk or protective) factors was also used in follow-up by telephone. For participants unable to be interviewed, the person who best knew the patient provided the information. Other factors to be ascertained included history of head injury, smoking, alcohol use, physical activities and leisure activities. Current medications were queried. In addition, for each medical condition or risk factor endorsed, the age at onset, duration, treatment history and whether there had been any change in the condition since the prior assessment was ascertained.

2.5 Biological Resources Collection. Initially, blood, saliva or frozen brain tissue collected at baseline and follow-up visits were sent to the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) which extracted and stored DNA. As shown in supplemental table 1, we collected DNA from 7,925 participants. In 2018, we expanded blood collection to also obtain peripheral blood mononuclear cells (PBMCs) at follow-up visits.

2.6 Genotyping and sequencing. Supplemental table 1 summarizes available genetic data. Genome wide SNP array (GWAS) data was obtained in 1,340 families (76.3%) in the cohort, which included 7,012 (72.4%) of their family members. Whole exome (WES) or whole genome sequencing (WGS) was conducted in 1,340 (76.3%) of the families. *APOE* genotyping was performed in 1,260 families (71.8%). The results of all genetic studies have been stored at the National Institute on Aging Genetics of Alzheimer's Disease Storage Site (NIAGADS).

2.7 Neuropathological confirmation of diagnosis. At the inception of the study, NIA-LOAD FBS began preplanning brain donation with all family members to maximize the likelihood that neuropathology would be performed after death. This resulted in a robust brain donation program in which autopsy reports or brain tissue was successfully obtained in 836 individuals (table 2). In the event an autopsy was performed, and no tissue was available, the autopsy report was requested. Brain autopsy was performed at Columbia University or at one of the study sites, with diagnoses based on the 2012 NIA-Alzheimer's Association Working Group guidelines²⁴. Brain tissue, frozen and fixed, were sent to NCRAD to share with the research community. In 2019 we expanded the use of brain

tissue to serve not only as a means to confirm diagnosis, but also to support functional studies including transcriptomics and DNA methylation studies.

3. Results

3.1 Demographics. Through a national effort, we recruited 1,756 families and acquired data from 9,682 family members. The families were diverse: 181(10.3%) African American, 425 (24.2%) Caribbean Hispanic, 138 (7.8%) self-reporting as “other or mixed” and 1,012 white, non-Hispanic (supplemental table 2). Among the affected and unaffected family members, 63% were women, a percentage that differed significantly by ethnic group (72% among African Americans and 66% among Hispanics, 62% among white non-Hispanics and 57% the other group, $p=0.009$). Among the 1,756 families, 451 (25.7%) had three or more affected family members. Another 31.5% had two affected individuals while 598 (34%) families consisted of only a single affected individual or a single individual who, after clinical evaluation, did not meet criteria for dementia or AD but had cognitive impairment. These families were still included for longitudinal observation. The proportions of affected to unaffected individuals was similar across the ethnic groups (supplemental table 2).

3.2 Data collection. In the family cohort, 8,610 (77.7%) individuals had detailed clinical information including multiple cognitive assessments. The other 22.3% were either too impaired for cognitive testing or were recruited before the clinical assessments were standardized in 2007. Tables 1 and 3 summarize the data collected and the resulting clinical diagnoses. Due to the national recruitment of families, we initiated telephone interviews several years ago to make it easier for family members to continue to participate. We conducted in-person interviews in 7,412 (68.5%) and follow-up interviews in 3,349 (30.9%). Because we had alternatives to in-person assessment in place prior to the pandemic, we were able to continue to follow family members; however, our ability to recruit new families was limited. Due to the length of this study, nearly 30 years for some families, 15.1% of the cohort has been lost to follow-up without leaving a forwarding address or telephone number, and 2,878 (26.6%) died.

3.3 Age-at-onset. The average age of onset in affected family members differed slightly, but significantly, across all ethnic groups ranging from 72 years in Caribbean Hispanics to 74 years in African Americans and white non-Hispanics ($p < 0.0001$). The average age at last visit among unaffected family members differed significantly by ethnic group (66.2 yrs, African American, 63.9 yrs, Hispanic vs. 68.7 yrs, white non-Hispanic; $p < 0.0001$).

We observed a very wide range of age-at-onset among the families with three or more affected members (figure 1). To explore the variation in onset age further we investigated families in which some individuals had their age-at-onset at least 10 or more years later than the mean for the family (figure 1b). Among these 132 families, the average age at onset was 71.79 years. Individuals with later ages-at-onset were significantly less likely to carry an *APOE-ε4* allele (44.9% vs. 60.5%) and more likely to carry an *APOE-ε3* allele (47.1% vs. 33.3%).

3.4 Genotyping. *APOE* genotyping revealed significant effects on the age-at-onset across all families, with similar effects in women and men (supplemental figures 2a and 2b). The *APOE-ε4* allele had the strongest effects in white, non-Hispanic families when the genotype was homozygous or heterozygous. However, among Caribbean Hispanics and African Americans the genotypic effects were limited to *APOE-ε4* homozygotes (supplemental figures 3a-d). These studies indicate that although *APOE* is a strong risk factor for sporadic AD, and also plays a role in familial AD.

3.4.1 Pathogenic variants. We found variants in *APP*, *PSEN1* and *PSEN2* associated with familial early onset forms of AD and *MAPT*, *GRN* and *C9orf72* with early onset forms of frontotemporal dementia (FTD). Sequencing these families have demonstrated that pathogenic variants in these genes can be also found in late-onset families²⁵⁻²⁹. The two more common pathogenic variants found in these families are the *PSEN1* p.A79V (0.46% of the families) and the *C9ORF72* expansion (0.48% of the families). Among the probands, 1.82% carried pathogenic variants in *APP*, *PSEN1*, and *PSEN2*, and 1.94% had pathogenic variants in *MAPT*, *GRN*, or *C9orf72*. These findings also imply that modifying factors may exist, either genetic or environmental, that delay the onset of disease in these late-onset families. Therefore, additional studies in the NIA-LOAD FBS are warranted to identify these novel modifier or protective variants.

Finding pathogenic variants usually associated with FTD among families with an AD phenotype could either indicate misdiagnosis or pleiotropy. Although autopsies were not available for all the individuals with FTD pathogenic variants, the neuropathology in some individuals, was compatible with a diagnosis of AD with mixed pathologies³⁰. *C9orf72* expansion has also been associated with several clinical presentations (FTD and ALS). The NIA-LOAD FBS extends these data to other genes and diseases, supporting the previous finding of pathogenic variants in FTD genes among individuals with AD pathology³¹.

3.5 Genomewide SNP Array. Despite the relatively modest size of the NIA-LOAD FBS data set, nominal significance in several loci, such as *CR1*, *CD2AP* and *EPHA1* contributed to several large AD meta-analyses (figure 2)³²⁻³⁴. The NIA-LOAD FBS dataset is also instrumental in the identification of additional risk variants. Recent studies using polygenic risk scores constructed based on summary statistics for disease risk for sporadic AD demonstrated that these families are enriched in genetic risk factors^{23,35}.

3.6 Neuropathological confirmation of diagnosis. In 492 (82%) participants, neuropathology confirmed the diagnosis of AD. Other diagnoses accounted for the remaining 163 with and without dementia (table 2). Brain tissue is available by request to NCRAD.

4. Discussion

The NIA-LOAD FBS began in 2003, with the collection and longitudinal follow up of large families multiply affected with AD. 1,885 DNA samples from 422 families were collected in the first three years from the NIA-funded AD Centers (ADC) throughout the United States. Subsequently, a goal was set to increase the collection to 1,000 families or more, to recruit all appropriate members in existing families, and initiate and complete follow-up. Blood samples from the participants were sent to the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) at Indiana University, for DNA extraction and storage allowing samples to be broadly available to the research community. Initially, clinical data regarding the diagnoses was limited to the criteria used by each Alzheimer's Disease Center, but in 2007 a more standardized approach was used to collect clinical information in a uniform fashion, to store it centrally at the Columbia University

Coordinating Center and to share it along with genetic data with the AD research community through NIAGADS. Nineteen dataset accession numbers contain genetic data from the NIA-LOAD FBS (table 4).

A genome wide association study (GWAS) was performed in the first 500 families, and data were deposited into the Database of Genotypes and Phenotypes (dbGaP) for broad sharing with the genetics community³⁶. In 2012, the Alzheimer's Disease Sequencing Project (ADSP) included the sequencing of 583 participants from 111 multiply affected families from the NIA-LOAD FBS^{29,37}. The ADSP Discovery Extension Study (2015-2018) included whole genome sequencing (WGS) on individuals from multiply affected families provided by the NIA-LOAD FBS. The ADSP Follow-Up Phase (2018-2023) heavily engaged resources from the NIA-LOAD FBS and depended on this project to conduct continued longitudinal follow up of families and the further collection of 500 additional families from under-represented populations. The characterization of additional relatives, the ascertainment of antecedent risk factors and the recruitment for autopsy benefits the research community by expanding the scientific value of the NIA-LOAD FBS. Thus, over the past two decades, the NIA-LOAD FBS has acted as the key source of biological materials, genetic and longitudinal clinical data on large multiply affected AD families from ethnically diverse populations.

The range of age-at-onset varied within and across families is shown in figure 1a and 1b. We hypothesize that individuals whose age-at-onset of AD is more than 10 years from the mean within their family may have benefited from an as yet unidentified genetic or epidemiologic protective factor. In fact, these individuals were significantly less like to harbor an *APOE-ε4* allele and more likely to have an *APOE-ε3* or *-ε2* allele. Similarly, those individuals whose age-at-onset was 10 years earlier than the mean within their family may harbor additional genetic or environmental risk factors. Phenotypic variation among members of a family with dementia, including differences in the age of onset and the effects of *APOE* or the presence of rapid eye movement (REM) sleep behavior disorder, psychosis and parkinsonism may be due to interactions with other genes or epigenetic effects. Brain transcriptomics and DNA methylation may help to clarify the origin of these differences. Moreover, because vascular risk factors clearly contribute to the pathogenesis of AD²³, the effects of cerebrovascular pathology remain to be defined.

As expected, the effects of *APOE* on the age-at-onset were statistically significant especially among white, non-Hispanics. In the homozygous genotype, the *APOE-ε4* allele was significantly associated with an earlier age at onset of disease regardless of ethnic group, but the effects of *APOE-ε4* heterozygosity on age-at-onset were limited to white, non-Hispanics. *APOE-ε4* showed similar effects in women and men.

The success of the NIA-LOAD FBS can be measured by the broad use of the data and samples (table 4). Over 67,000 biological samples collected as part of the NIA-LOAD FBS have been distributed to approved investigators. These samples have been analyzed, and the resulting data are available through the database of Genotypes and Phenotypes (dbGaP) and NIAGADS. In total, over 830 national and international investigators have requested data from the NIA-LOAD FBS, including the Alzheimer's Disease Genetics Consortium (ADGC), the Alzheimer's Disease Sequencing Project (ADSP), the Consortium for Alzheimer's Disease Research (CADRE), the NIA-sponsored Alzheimer's Disease Research Centers (ADRCs) and the National Alzheimer's Coordinating Center (NACC). Investigators have generated 126 publications from the data and samples (Supplement 4).

Multiplex families are more difficult to recruit for research studies, sometimes taking several years to identify all of the affected relatives in a single family and complete their phenotyping. Large multiplex families are often thought to be too rare to be relevant. However, such families may actually be much more common than assumed, and there are families in isolated geographical regions where very large sibships occur.³⁸⁻⁴⁰ Families with multiple ill members can more easily be found and ascertained for such studies. With the increased use of virtual visits, the ability to longitudinally follow these families is becoming easier. These large multiplex families may hold the key to survival without dementia despite carrying a disease-causing variant.

The ultimate aims of genetic studies of complex diseases, such as AD, are to identify causal biological pathways that might provide targets for therapeutic development. However, diseases such as AD are multigenic and it is likely that there are multiple strategies to accomplish this difficult task. A significant proportion of the heritability remains unexplained but may be due to rare, inherited, moderately penetrant variants unique to individual families. The NIA-LOAD FBS remains a critical component of the overall strategy to tackle AD genetics in the

United States that includes the Alzheimer's Disease Genetics Consortium, the Alzheimer's Disease Sequencing Project, the NCRAD and NIAGADS. Together these groups have created a large collaborative international effort to combine data worldwide in pursuit of uncovering the relevant genetic risk factors for AD with the hope that patterns may emerge that ultimately will uncover biologic pathways underlying the illness.

Acknowledgements: The NIA-LOAD FBS supported the collection of samples used in this study through National Institute on Aging (NIA) grants U24AG026395, U24AG021886, R01AG041797 and U24AG056270. Additional families were contributed to the NIA-LOAD FBS through NIH grants: R01AG028786, R01AG027944, RO1AG027944, RF1AG054074, U01AG052410. We thank contributors, including the Alzheimer's Disease Centers who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible.

References

1. Association As. Alzheimer's Disease Facts and Figure. https://www.alz.org/alzheimers-dementia/facts-figures?utm_source=google&utm_medium=paidsearch&utm_campaign=google_grants&utm_content=alzheimers&gclid=EAlaQobChMI8MGnp9HY7glVlxxlCh2vXwP0EAAYASAAEgK9U_D_BwE. Published 2020. Accessed.
2. Chartier-Harlin MC, Crawford F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. *Nature*. 1991;353(6347):844-846.
3. Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. *Science*. 1992;258(5082):668-671.
4. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature*. 1995;375(6534):754-760.
5. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science*. 1995;269(5226):973-977.
6. Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. *Science*. 1995;269(5226):970-973.
7. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. *J Geriatr Psychiatry Neurol*. 2010;23(4):213-227.
8. Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. *Am J Hum Genet*. 1999;65(3):664-670.
9. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. *Alzheimers Dement (N Y)*. 2020;6(1):e12050.
10. Pericak-Vance MA, Bebout JL, Gaskell PC, Jr., et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. *Am J Hum Genet*. 1991;48(6):1034-1050.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993;261(5123):921-923.
12. Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. *Neuron*. 2019;101(5):820-838.

13. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*. 1997;278(16):1349-1356.
14. Slioter AJ, Cruts M, Kalmijn S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. *Arch Neurol*. 1998;55(7):964-968.
15. Lee JH, Kahn A, Cheng R, et al. Disease-related mutations among Caribbean Hispanics with familial dementia. *Mol Genet Genomic Med*. 2014;2(5):430-437.
16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):263-269.
17. Wilson RS, Leurgans SE, Foroud TM, et al. Telephone assessment of cognitive function in the late-onset Alzheimer's disease family study. *Arch Neurol*. 2010;67(7):855-861.
18. Wilson RS, Barral S, Lee JH, et al. Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. *J Alzheimers Dis*. 2011;23(2):249-255.
19. Hollingworth P, Sweet R, Sims R, et al. Genome-wide association study of Alzheimer's disease with psychotic symptoms. *Mol Psychiatry*. 2012;17(12):1316-1327.
20. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. *Neurology*. 1997;48(5 Suppl 6):S10-16.
21. Hamilton M. Development of a rating scale for primary depressive illness. *Br J Soc Clin Psychol*. 1967;6(4):278-296.
22. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. *J Neuropsychiatry Clin Neurosci*. 2000;12(2):233-239.
23. Tosto G, Bird TD, Bennett DA, et al. The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. *JAMA Neurol*. 2016;73(10):1231-1237.
24. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol*. 2012;123(1):1-11.

25. Barral S, Cheng R, Reitz C, et al. Linkage analyses in Caribbean Hispanic families identify novel loci associated with familial late-onset Alzheimer's disease. *Alzheimers Dement*. 2015;11(12):1397-1406.
26. Blue EE, Bis JC, Dorschner MO, et al. Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project. *Dement Geriatr Cogn Disord*. 2018;45(1-2):1-17.
27. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS One*. 2012;7(2):e31039.
28. Fernandez MV, Kim JH, Budde JP, et al. Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. *PLoS Genet*. 2017;13(11):e1007045.
29. Vardarajan BN, Barral S, Jaworski J, et al. Whole genome sequencing of Caribbean Hispanic families with late-onset Alzheimer's disease. *Ann Clin Transl Neurol*. 2018;5(4):406-417.
30. Harms M, Benitez BA, Cairns N, et al. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. *JAMA Neurol*. 2013;70(6):736-741.
31. Kohli MA, John-Williams K, Rajbhandary R, et al. Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. *Neurobiol Aging*. 2013;34(5):1519 e1515-1512.
32. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*. 2013;45(12):1452-1458.
33. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet*. 2019;51(3):414-430.
34. Jansen IE, Savage JE, Watanabe K, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet*. 2019;51(3):404-413.
35. Tosto G, Bird TD, Tsuang D, et al. Polygenic risk scores in familial Alzheimer disease. *Neurology*. 2017;88(12):1180-1186.
36. Wijsman EM, Pankratz ND, Choi Y, et al. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. *PLoS Genet*. 2011;7(2):e1001308.

37. Beecham GW, Vardarajan B, Blue E, et al. Rare genetic variation implicated in non-Hispanic white families with Alzheimer disease. *Neurol Genet*. 2018;4(6):e286.
38. Athan ES, Williamson J, Ciappa A, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. *JAMA*. 2001;286(18):2257-2263.
39. Lalli MA, Cox HC, Arcila ML, et al. Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. *Alzheimers Dement*. 2014;10(5 Suppl):S277-S283 e210.
40. Lee JH, Cheng R, Vardarajan B, et al. Genetic Modifiers of Age at Onset in Carriers of the G206A Mutation in PSEN1 With Familial Alzheimer Disease Among Caribbean Hispanics. *JAMA Neurol*. 2015;72(9):1043-1051.

Figure Legends

Figure 1a. Distribution of age-at-onset among 451 families with three or more members affected by AD. The blue horizontal line represents the mean age at onset for each family, while the gray vertical lines represent the range of onset ages within each family.

Figure 1b. Distribution of age-at-onset among 132 families with three or more members affected by AD and with a delay in onset by 10 years or more from the mean age-at-onset in the family. The blue horizontal line represents the mean age at onset for each family, while the gray vertical lines represent the range of onset ages within each family.

Figure 2. Results of genome-wide array in the NIA-LOAD FBS. The APOE locus reached genome-wide significance in associated with AD. However, a number of other loci, labeled on the Manhattan plot below were nominally significant. Many of these loci supported several large meta-analyses that included other cohorts³²⁻³⁴.